The Front Room — a clinical regulatory commons
RSS
← Back to feed

Baxfendy cleared as first aldosterone synthase inhibitor for hypertension

Sponsor
AstraZeneca $AZN
Drug
Baxfendy · baxdrostat
Indication
hypertension
More on AstraZeneca ↗ Google News

FDA approved AstraZeneca's Baxfendy (baxdrostat) as the first aldosterone synthase inhibitor for hypertension in combination with other antihypertensive medications.

What this means

Baxfendy is a blood pressure medication that works by blocking aldosterone production, a hormone that can cause stubborn high blood pressure. The FDA just approved Baxfendy for use alongside other blood pressure drugs in patients who need additional treatment. This gives doctors a new tool for hard-to-control hypertension by targeting a different pathway than existing medications.

Read original at accessdata.fda.gov ↗
Topic hypertension

Drug Watch — recent news on Baxfendy

Sponsor Watch — recent news on AstraZeneca